RCKT submitted a Rule 144 notice disclosing 3,361 shares of Common Stock tied to a restricted stock vesting event dated 05/11/2026.
The filing also lists prior sales by Martin Wilson of 12,253 shares on 02/13/2026 for $40,583.16 and 1,376 shares on 02/18/2026 for $4,593.78.
RCKT submitted a Rule 144 notice disclosing 3,361 shares of Common Stock tied to a restricted stock vesting event dated 05/11/2026.
The filing also lists prior sales by Martin Wilson of 12,253 shares on 02/13/2026 for $40,583.16 and 1,376 shares on 02/18/2026 for $4,593.78.
Rocket Pharmaceuticals (RCKT) filed a Form 144 reporting proposed sales tied to recent restricted stock vesting. The filing lists 2,728 shares in a restricted stock vesting entry dated 05/11/2026 and two past reported dispositions by Gaurav Shah of 12,279 and 5,990 shares on 02/13/2026 and 02/18/2026, with associated dollar figures shown in the excerpt.
Rocket Pharmaceuticals (RCKT) filed a Form 144 reporting proposed sales tied to recent restricted stock vesting. The filing lists 2,728 shares in a restricted stock vesting entry dated 05/11/2026 and two past reported dispositions by Gaurav Shah of 12,279 and 5,990 shares on 02/13/2026 and 02/18/2026, with associated dollar figures shown in the excerpt.
RCKT submitted a Form 144 reporting 855 shares of Common Stock to be sold in connection with Restricted Stock Vesting on 05/11/2026.
The filing also records prior sales: 3,726 shares on 02/13/2026 for $12,340.88 and 1,157 shares on 02/18/2026 for $3,862.64.
RCKT submitted a Form 144 reporting 855 shares of Common Stock to be sold in connection with Restricted Stock Vesting on 05/11/2026.
The filing also records prior sales: 3,726 shares on 02/13/2026 for $12,340.88 and 1,157 shares on 02/18/2026 for $3,862.64.
ROCKET PHARMACEUTALS, INC. insider Sarbani Chaudhuri reported an open-market sale of 17,650 shares of common stock at $3.838 per share on May 7, 2026. According to the disclosure, the shares were sold to cover tax withholding obligations arising from the vesting of restricted stock units (RSUs). After this transaction, Chaudhuri holds 267,510 shares of common stock, which includes RSUs that convert into common stock on a one-for-one basis.
ROCKET PHARMACEUTALS, INC. insider Sarbani Chaudhuri reported an open-market sale of 17,650 shares of common stock at $3.838 per share on May 7, 2026. According to the disclosure, the shares were sold to cover tax withholding obligations arising from the vesting of restricted stock units (RSUs). After this transaction, Chaudhuri holds 267,510 shares of common stock, which includes RSUs that convert into common stock on a one-for-one basis.
Rocket Pharmaceuticals, Inc. reported first quarter 2026 results and highlighted major pipeline and financing milestones. The company received FDA accelerated approval for KRESLADI for severe LAD-I and monetized a Rare Pediatric Disease Priority Review Voucher for $180 million.
Pro forma cash, cash equivalents and investments were approximately $322.6 million, providing an expected operational runway into the second quarter of 2028. For the three months ended March 31, 2026, Rocket recorded a net loss of $47.6 million compared with $61.3 million a year earlier, with total operating expenses declining to $48.5 million from $64.4 million. Cash, cash equivalents and investments were $144.4 million as of March 31, 2026.
Rocket Pharmaceuticals, Inc. reported first quarter 2026 results and highlighted major pipeline and financing milestones. The company received FDA accelerated approval for KRESLADI for severe LAD-I and monetized a Rare Pediatric Disease Priority Review Voucher for $180 million.
Pro forma cash, cash equivalents and investments were approximately $322.6 million, providing an expected operational runway into the second quarter of 2028. For the three months ended March 31, 2026, Rocket recorded a net loss of $47.6 million compared with $61.3 million a year earlier, with total operating expenses declining to $48.5 million from $64.4 million. Cash, cash equivalents and investments were $144.4 million as of March 31, 2026.
Rocket Pharmaceuticals reported another quarterly loss as it transitions to commercial stage. For the three months ended March 31, 2026, the company generated no revenue and recorded a net loss of $47.6 million versus $61.3 million a year earlier, as both research and development and general and administrative expenses declined.
Cash, cash equivalents and investments totaled $144.4 million as of March 31, 2026. In March, the FDA granted accelerated approval for KRESLADI™ for severe LAD‑I, and in April the company signed a definitive agreement to sell the related Priority Review Voucher for $180 million, which management expects will provide non‑dilutive funding to support its cardiovascular gene therapy pipeline and extend its operating runway by at least twelve months. Rocket also continues to face class action and derivative litigation tied to disclosures about its Danon disease program.
Rocket Pharmaceuticals reported another quarterly loss as it transitions to commercial stage. For the three months ended March 31, 2026, the company generated no revenue and recorded a net loss of $47.6 million versus $61.3 million a year earlier, as both research and development and general and administrative expenses declined.
Cash, cash equivalents and investments totaled $144.4 million as of March 31, 2026. In March, the FDA granted accelerated approval for KRESLADI™ for severe LAD‑I, and in April the company signed a definitive agreement to sell the related Priority Review Voucher for $180 million, which management expects will provide non‑dilutive funding to support its cardiovascular gene therapy pipeline and extend its operating runway by at least twelve months. Rocket also continues to face class action and derivative litigation tied to disclosures about its Danon disease program.
Rocket Pharmaceuticals, Inc. has entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher for $180 million in cash, payable at closing. The voucher was granted after FDA accelerated approval of KRESLADI, Rocket’s gene therapy for severe LAD-I.
Rocket states that monetizing the voucher provides meaningful non-dilutive capital and extends its cash runway into the second quarter of 2028. The company plans to use the proceeds to support its prioritized cardiovascular gene therapy pipeline, including clinical programs in Danon disease, PKP2-associated arrhythmogenic cardiomyopathy and BAG3-associated dilated cardiomyopathy.
Rocket Pharmaceuticals, Inc. has entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher for $180 million in cash, payable at closing. The voucher was granted after FDA accelerated approval of KRESLADI, Rocket’s gene therapy for severe LAD-I.
Rocket states that monetizing the voucher provides meaningful non-dilutive capital and extends its cash runway into the second quarter of 2028. The company plans to use the proceeds to support its prioritized cardiovascular gene therapy pipeline, including clinical programs in Danon disease, PKP2-associated arrhythmogenic cardiomyopathy and BAG3-associated dilated cardiomyopathy.
Rocket Pharmaceuticals is calling a virtual 2026 annual stockholder meeting on May 20, 2026, to vote on four key items: electing seven directors, ratifying EisnerAmper LLP as auditor, a non-binding advisory vote on executive pay, and approving a stock option exchange program.
Stockholders of record on March 24, 2026, when 109,122,837 common shares were outstanding, may vote online or by proxy. The proxy also describes a 2025 strategic reorganization that cut headcount by about 30% and is expected to lower 12‑month operating expenses by nearly 25%, along with a pay-for-performance executive compensation framework that received about 98% support in the 2025 advisory vote.
Rocket Pharmaceuticals is calling a virtual 2026 annual stockholder meeting on May 20, 2026, to vote on four key items: electing seven directors, ratifying EisnerAmper LLP as auditor, a non-binding advisory vote on executive pay, and approving a stock option exchange program.
Stockholders of record on March 24, 2026, when 109,122,837 common shares were outstanding, may vote online or by proxy. The proxy also describes a 2025 strategic reorganization that cut headcount by about 30% and is expected to lower 12‑month operating expenses by nearly 25%, along with a pay-for-performance executive compensation framework that received about 98% support in the 2025 advisory vote.
Rocket Pharmaceuticals Inc reported an amendment to institutional holdings showing 0 shares beneficially owned by The Vanguard Group after an internal realignment. The filing states that, following the realignment described in January 12, 2026, certain Vanguard subsidiaries will report holdings separately.
The Schedule 13G/A lists Amount beneficially owned: 0 and Percent of class: 0%. The filing is signed by Ashley Grim on March 27, 2026.
Rocket Pharmaceuticals Inc reported an amendment to institutional holdings showing 0 shares beneficially owned by The Vanguard Group after an internal realignment. The filing states that, following the realignment described in January 12, 2026, certain Vanguard subsidiaries will report holdings separately.
The Schedule 13G/A lists Amount beneficially owned: 0 and Percent of class: 0%. The filing is signed by Ashley Grim on March 27, 2026.